LitAlert ~~ GeneLit.com

Increased prevalence of BRCA1/2 mutations in women with macro-textured breast implants and anaplastic large cell lymphoma of the breast.
De Boer M, Hauptmann M, Hijmering NJ, van Noesel CJM, Rakhorst HA, Meijers-Heijboer HE, Boer JP, van der Hulst RR, De Jong D, van Leeuwen FE.
Blood. 2020 May 26:blood.2019004498. doi: 10.1182/blood.2019004498. Epub ahead of print.

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B.
Oncologist. 2020 May 26. doi: 10.1634/theoncologist.2020-0039. Epub ahead of print.

Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer.
Algebaly AS, Suliman RS, Al-Qahtani WS.
Clin Transl Oncol. 2020 May 25. doi: 10.1007/s12094-020-02385-9. Epub ahead of print.

PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
Kurnit KC, Avila M, Hinchcliff E, Coleman RL, Westin SN.
Pharmacol Ther. 2020 May 22:107588. doi: 10.1016/j.pharmthera.2020.107588. Epub ahead of print.